Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
MedlinePlus | a685019 |
Routes of administration | IM, IV |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 90% |
Metabolism | <30% hepatic |
Elimination half-life | 0.5 hours |
Excretion | Biliary and renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.174 |
Chemical and physical data | |
Formula | C21H22N2O5S |
Molar mass | 414.48 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Nafcillin sodium is a narrow-spectrum[1] beta-lactam antibiotic[2] of the penicillin class. As a beta-lactamase-resistant penicillin, it is used to treat infections caused by Gram-positive bacteria, in particular, species of staphylococci that are resistant to other penicillins.
Nafcillin is considered therapeutically equivalent to oxacillin, although one retrospective study found greater rates of hypokalemia and acute kidney injury in patients taking nafcillin compared to patients taking oxacillin.[3]